SABCS 2023 | CAMBRIA 1: camizestrant ER+/HER2- early breast cancer

Erika Hamilton, MD, Sarah Cannon Research Institute, Nashville, TN, discusses the Phase III open-label CAMBRIA 1 study (NCT05774951), investigating camizestrant, the oral selective estrogen receptor degrader (SERD), compared to standard endocrine therapy in patients with ER+/HER2- early breast cancer. Patients enrolled had previously completed standard adjuvant endocrine therapy (ET) for at least 2 years prior. Dr Hamilton indicates that the CAMBRIA 1 trial will hopefully highlight whether camizestrant is a promising alternative to ET for patients with ER+/HER2- early breast cancer. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) congress in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.